Apexigen, Inc. Price & Performance (APGN)

In a significant restructuring move, Mural Oncology announced it is cutting 90% of its workforce as it explores strategic alternatives. This development follows a broader trend in the pharmaceutical sector, including Pfizer's ongoing cost-saving measures and Vincerx Pharma's recent decision to wind down operations.12

Pyxis Oncology is pivoting towards a single-candidate strategy, laying off 20% of its staff. This follows a previous 40% workforce reduction after acquiring Apexigen. The company aims to focus on its sole clinical candidate, micvotabart pelidotin, as it navigates a challenging biotech market.3

Apollo.io's stock remains a focal point for investors following its Series D funding round, which raised $100.65 million. With a valuation of $1.6 billion, backed by major investors like Bain Capital Ventures and Sequoia Capital, the company's growth trajectory continues to attract significant market attention.4